Similar articles

• Statement 5: the first line of treatment for children with idiopathic short stature (ISS) and low serum insulin-like growth factor-I (IGF-I) should be IGF-I.

  Backeljauw P. Backeljauw P. Pediatr Endocrinol Rev. 2008 Apr;5 Suppl 3:853-6. Pediatr Endocrinol Rev. 2008. PMID: 18438329 Review. No abstract available.
• Experience with insulin-like growth factor I (IGF-I) treatment of growth hormone insensitivity syndrome (GHIS).

  Ranke MB, Wollmann HA, Savage MO. Ranke MB, et al. J Pediatr Endocrinol Metab. 1999 Apr;12 Suppl 1:259-66. J Pediatr Endocrinol Metab. 1999. PMID: 10698590 Review. No abstract available.
• The molecular basis of idiopathic short stature.

  Rosenfeld RG. Rosenfeld RG. Growth Horm IGF Res. 2005 Jul;15 Suppl A:S3-5. doi: 10.1016/j.ghir.2005.06.014. Growth Horm IGF Res. 2005. PMID: 16023877 Review.
• Insulin-like growth factor I and growth responses during the first year of growth hormone treatment in KIGS patients with idiopathic growth hormone deficiency, acquired growth hormone deficiency, turner syndrome and born small for gestational age.

  Cutfield WS, Lundgren F. Cutfield WS, et al. Horm Res. 2009 Jan;71 Suppl 1:39-45. doi: 10.1159/000178036. Epub 2009 Jan 21. Horm Res. 2009. PMID: 19153504
• Therapy of growth disorders.

  Ali O, Wyatt D. Ali O, et al. Curr Opin Endocrinol Diabetes Obes. 2011 Feb;18(1):3-8. doi: 10.1097/MED.0b013e328341f873. Curr Opin Endocrinol Diabetes Obes. 2011. PMID: 21150587 Review.